Q3 2016 EPS Estimates for Mirna Therapeutics Inc. (MIRN) Raised by Analyst
Mirna Therapeutics Inc. (NASDAQ:MIRN) – Investment analysts at Leerink Swann boosted their Q3 2016 EPS estimates for Mirna Therapeutics in a report issued on Tuesday. Leerink Swann analyst M. Schmidt now anticipates that the brokerage will earn ($0.29) per share for the quarter, up from their previous estimate of ($0.46). Leerink Swann currently has a “Neutral” rating on the stock. Leerink Swann also issued estimates for Mirna Therapeutics’ Q4 2016 earnings at ($0.29) EPS, FY2016 earnings at ($1.17) EPS and FY2017 earnings at ($1.73) EPS.
Several other brokerages have also recently issued reports on MIRN. HC Wainwright cut shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $6.00 to $2.00 in a research note on Friday. Zacks Investment Research raised shares of Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research note on Wednesday, September 7th. Oppenheimer Holdings Inc. cut shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Citigroup Inc. dropped their price objective on shares of Mirna Therapeutics from $4.50 to $2.00 and set a “neutral” rating on the stock in a research note on Thursday. Finally, Cantor Fitzgerald cut shares of Mirna Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the company from $14.00 to $2.00 in a research note on Wednesday. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Mirna Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $4.29.
Shares of Mirna Therapeutics (NASDAQ:MIRN) remained flat at $1.96 during midday trading on Friday. 30,184 shares of the stock traded hands. Mirna Therapeutics has a one year low of $1.82 and a one year high of $11.01. The company’s market capitalization is $40.84 million. The stock has a 50-day moving average price of $3.05 and a 200-day moving average price of $4.08.
About Mirna Therapeutics
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.